Kyver­na says CAR-T man­u­fac­tur­ing times can be cut through blood col­lec­tion ef­fi­cien­cies 

Clin­i­cal-stage biotech Kyver­na Ther­a­peu­tics re­vealed fur­ther de­tails on how it can po­ten­tial­ly short­en pro­duc­tion time­lines for au­toim­mune CAR-Ts by us­ing its so-called “vein-to-vein” process.

Kyver­na, which has CAR-T as­sets un­der in­ves­ti­ga­tion in au­toim­mune dis­eases, on Wednes­day pub­lished de­tails in bioRx­iv for its pro­ce­dure called In­genui-T, which it de­vel­oped with cell and gene man­u­fac­tur­er El­e­vate­Bio, a col­lab­o­ra­tion pre­vi­ous­ly an­nounced in Sep­tem­ber last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER